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ABSTRACT
To initiate, monitor, and complete effective immunotherapy, biomarkers to predict and visualize the immune re-
sponses are needed. First, we need to identify the right candidate for immunotherapy. Secondly, the immune
responses induced by immunotherapy should be monitored. For the first objective, analysis of polymorphisms
of candidate genes may be helpful, but still be in development. Regarding biomarkers for immune responsese,
there are numerous reports that evaluate immunotherapy-induced immune changes such as suppression of ef-
fector cells, deviation to Th1 cytokine production, and induction of regulatory T cells. No standardized methods,
however, have been established. Among them, a functional assay of blocking IgG activity, the IgE-facilitated al-
lergen binding assay, may be useful. We quantitated induced expression of an activation marker, CD203c, on
basophils and found that the assay efficiently predicts sensitivity to particular allergen and severity of the
allergen-induced symptoms. In patients who received rush immunotherapy for Japanese cedar pollinosis, re-
duction in CD203c expression after the therapy was observed, suggesting the utility of the test for monitoring
immunotherapy.
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INTRODUCTION
The incidence of Japanese cedar pollinosis (JCP) is
increasing at an astonishing pace, which was first rec-
ognized in early 1960s and now affects around one
fourth of the population in Japan.1-3 Effective pharma-
cotherapy including non-sedating antihistamines, leu-
kotriene receptor antagonists, and topical corticoster-
oids, has evolved and quality of life of the patients has
been improving.4,5 Yet, the remedies merely control
symptoms and do not change natural history of the
disease. Further, social burden of the disease is still
significant.6 On the other hand, allergen immunother-
apy generally not only alleviate allergic symptoms but
has potential to modify the disease since clinical
benefits are reported to be maintained at least for 3
years, even for 12 years after discontinuation.7,8 In
children, immunotherapy prevents new sensitiza-
tions9,10 and reduces progression of rhinitis to asthma
for up to 10 years.11 Long-term efficacy of immuno-
therapy in Japanese cedar pollinosis has also been re-
ported.12
Although immunotherapy confers a multitude of
benefits, there still exist issues to be addressed; the
present form of immunotherapy is still bound to IgE-
mediated side effects, some patients may not benefit
from the treatment, long periods for treatment are re-
quired and the timing of stopping therapy is not well
defined. Along with various efforts to improve the
therapy, effective biomarkers have to be developed to
tailor the existing therapy and to evaluate new forms
of the therapy. The markers should identify right pa-
tients with favorable therapeutic responses without
adverse events, monitor the efficacy based on immu-
nological responses to particular allergen, and iden-
tify the right timing of discontinuation. Although
“ideal” biomarkers are yet to be established, pros-
pects for the biomarkers in allergen immunotherapy
will be discussed in this article. We also describe
quantification of allergen-induced CD203c expression
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Fig. 1 Mechanisms of alergen immunotherapy.
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on basophils as a possible biomarker for Japanese ce-
dar pollinosis. Basophils are important effector cells
in the pathogenesis of allergic diseases13 because
they infiltrate in the nasal mucosa of patients with al-
lergic rhinitis14 and produce a number of mediators
and cytokines involved in immediate and late allergic
responses.15 In addition, the fact being circulating
cells easily enables us to test the cells ex vivo by util-
izing a flowcytometry. Here, we show that the baso-
phil activation test utilizing CD203c expression may
measure “blocking” activity induced by immunother-
apy.
IMMUNOLOGICAL MECHANISMS IN AL-
LERGEN IMMUNOTHERAPY
THE ALLERGIC RESPONSE
Before discussing biomarkers in allergen immuno-
therapy, the putative immunological mechanisms are
summarized (Fig. 1). The exposure of cedar allergen
in the nose, eyes, or bronchi of genetically suscepti-
ble individuals causes Th2-deviated immune re-
sponses. Cytokines such as IL-4, IL-5, IL-9, and IL-13
derived from Th2 cells are responsible for specific
IgE production, differentiation and activation of effec-
tor cells such as mast cells, basophils, and eosino-
phils, and direct stimulation of responder organs in-
cluding mucus glands and vascular cells in the af-
fected organ. Upon re-exposure to the allergen in the
season, IgE-dependent activation of mast cells and ba-
sophils results in release of numerous mediators in-
cluding histamine, cysteinyl leukotrienes, prostaglan-
dins, and platelet activating factor, leading to sneeze,
pruritus, waterly discharge, stuffy nose, and some-
times bronchospasm. In addition, mast cells and ba-
sophils, are large producers of Th2 and proinflamma-
tory cytokines including IL-4 and TNF-α to potentiate
chronic Th2-deviated inflammation in the tissue.
Allergen immunotherapy has potential to inhibit or
reverse each step of the above allergic responses and
to confer tolerance to the allergen (Fig. 1). Signifi-
cantly higher amount of allergen is administered in
immunotherapy compared to natural exposure. Be-
cause it has been shown that deviation to Th2 as ex-
pressed by IgE production depends on the allergen
dose used to prime the corresponding experimental
systems,16-18 where low allergen doses favor and high
allergen dose suppress IgE production. In fact, clini-
cal efficacy is related to the allergen dose,19,20 higher
doses results in better protection.
MECHANISMS OF IMMUNOTHERAPY IN THE
EFFECTOR PHASE
Recently, time course analysis of clinical and immu-
nologic measurements during the first year of grass
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Table 1 Development of biomarkers for alergen immuno-
therapy
・Patient selection
 Prediction of therapeutic responses
 Prediction of serious adverse reactions
 Identification of candidates for secondary prevention
・Maintenance
 Monitoring of “protective” immune responses
・“Blocking” antibodies
・ Regulatory T cels, IL-10 and other inhibitory cytokines
・Suppression of efector cels: mast cels, basophils, 
eosinophils
 Prediction of serious adverse reactions
・Completion
 Identification of “normalized” immune responses to al-
lergen
 Prediction of recurence after discontinuation
pollen immunotherapy21 has been reported, which
could substantiate a number of partial information
previously observed. The first change was reduction
of late phase responses (LPR) to intradermal chal-
lenge testing that was observed as early as after the
first 2 weeks during up-dosing stage of the conven-
tional injection immunotherapy. Then, elevation of
specific IgG4, inhibition of basophil histamine re-
lease, and inhibition of binding of allergen-IgE com-
plex to B cells were observed during 6 to 8 weeks at
maintenance allergen doses. Reduction of early skin
responses, which usually associates with clinical effi-
cacy, was accompanied with these later immunologi-
cal changes. The investigators also found that
allergen-induced IL-10 production from peripheral
blood mononuclear cells was a very early event ac-
companied with LPR suppression. They concluded
that IgG responses may be necessary for clinical pro-
tection, inhibition of histamine release and allergen
IgE binding to B cells, but that the preceding IL-10
production could contribute to this process.
MECHANISM OF IMMUNOTHERAPY IN T CELL
DIFFERENTIATION
The important upstream events that immunotherapy
bring about in immune responses to allergen is T cell
differentiation, a critical step in regulating down-
stream effector mechanisms. Cumulative evidence re-
vealed that Th1 cells and T regulatory cells are the
key cells in this context.
First, in patients who received grass pollen immu-
notherapy, increase in cells expressing IFN-γ mRNA
were found in the nasal mucosa during allergen-
induced late responses and the number of the cells
and symptoms scores were inversely correlated.22 IL-
12 is known to be a major cytokine to induce IFN-γ-
producing Th1 cells and significant increases in
allergen-induced IL-12 mRNA+ cells in cutaneous bi-
opsy specimens was observed in the immunotherapy-
treated patients and IL-12+ cells correlated positively
with IFN-γ+ cells, inversely with IL-4+ cells.23 In
terms of Th2 cells, seasonal increases in IL-5 and IL-
9-expressing cells in the nasal mucosa were signifi-
cantly inhibited in immunotherapy patients.24,25 Col-
lectively, Th1 cells are induced and Th1Th2 balance
is altered in favor of Th1 cells by immunotherapy.
There are several subsets of T regulatory cells26
and there exists inappropriate balance between aller-
gen activation of regulatory T cells and effector Th2
cells in allergy. It was reported that CD4+CD25+ T
cells, so-called naturally occurring regulatory T cells
(nTreg), from non-allergic donors suppressed prolif-
eration and IL-5 production by their own allergen-
stimulated CD4+CD25− cells while the inhibition by
CD4+CD25+ T cells from allergy patients were signifi-
cantly reduced.27 For these conditions, immunother-
apy induces regulatory T cells in the treated patients,
so called inducible regulatory T cells (Tr1 cells) and
many studies have constantly identified induced ex-
pression of IL-10.21,28-30 One report demonstrated that
local increases in IL-10 mRNA and protein-positive
cells were observed in the nasal mucosa from pa-
tients after 2 years of grass pollen immunotherapy.
The changes were observed in treated patients only
during the pollen season, not during off-season, nor
in placebo-treated subjects and healthy controls.30
These results suggest that IL-10 responses are
allergen-specific, inducible phenomenon. IL-10 acts
on B cells to induce production of IgG4.31 IL-10-
induced “blocking” IgG4 inhibits mast cell histamine
release and IgE-facilitated allergen-binding to B cells.
IL-10 also directly blocks IgE-mediated mast cell acti-
vation.32 Further, IL-10 blocks T cell activation by in-
hibiting costimulatory molecule CD28 signaling path-
way,33 leading to reduction in cytokines such as IL-534
and reduction in inflammatory cell recruitment such
as eosinophils.24
BIOMARKERS TO MONITOR ALLERGEN
IMMUNOTHERAPY
To initiate, monitor, and complete effective immuno-
therapy, biomarkers to predict and visualize the im-
mune responses are needed (Table 1). First, we need
to identify the right candidate for immunotherapy. Al-
though the present form of immunotherapy is effec-
tive, some patients may not respond to well the ther-
apy and some may suffer from serious adverse
events. We have to select ones who will benefit most.
It has been shown that immunotherapy for children
with rhinitis prevented “atopic march” from advanc-
ing to asthma.11 We have to select the right child for
the intervention since not all children with rhinitis de-
velop asthma. Recent progress in genetics has led to
the identification of several candidate genes that are
associated with various phenotypes of allergic dis-
eases.35 It is hopeful in the future that novel genetic
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Fig. 2 Flowcytometric analysis of alergen-induced expression of CD203c. EDTA-containing whole blood was incu-
bated with various concentrations of the Japanese cedar polen (JCP) extract (Tori Pharmaceutical, Tokyo, Japan) for 
15 min after addition of suficient amount of calcium solution to overide chelating capacity of EDTA. Anti-IgE antibody 
as a positive control and PBS as a negative control were also used for stimulation (c). PC7-conjugated anti-CD3, FITC-
conjugated anti-CRTH2, and PE-conjugated anti-CD203c antibodies were also added during the reaction. The samples 
were analyzed on a FC500 flow cytometer (Beckman Coulter, CA, USA). Basophils were detected on the basis of for-
ward side scater characteristics (a) and expression of negative CD3 (b) and positive CRTH2 (c). Up-regulation of 
CD203c on basophils was determined using a threshold that was defined by the fluorescence of unstimulated cels 
(negative control) and expressed as CD203chigh% (c). JCP extract induced concentration-dependent enhancement of 
CD203c expression in a patient with JCP polinosis (d) and no enhancement was observed in a normal control (e).
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biomarkers identify patients who respond to the ther-
apy without risk of developing side effects.36
Secondly, the immune responses induced by im-
munotherapy need to be evaluated. Based on the
knowledge of the mechanisms of immunotherapy,
several assays have been reported. Studies of periph-
eral blood mononuclear cells from patients receiving
immunotherapy have identified reductions in prolif-
erative responses to allergen, shifts from Th2 to Th2
cytokine production, and enhanced inhibitory IL-10
production.25,28,31,37 Some investigators, however, did
not reproduce these findings in assays using periph-
eral blood although changes in the local tissue were
demonstrated.38 Variations in methodology in the pe-
ripheral T cell assays may be responsible for the dis-
crepancies and standardization is necessary. Eleva-
tion of serum allergen-specific IgG or IgG4 antibodies
after immunotherapy have been clearly demonstrated
but again correlation between IgG or IgG4 titers and
clinical responses to immunotherapy still to be estab-
lished. Instead, functional assay of blocking IgG activ-
ity have been developed. Among them, the IgE-
facilitated allergen binding (IgE-FAB) assay is re-
ported to be a validated assay for monitoring allergen
immunotherapy.39 Receptors for IgE, expressed on
the surface of antigen presenting cells, B cells in this
assay system, facilitate the presentation of allergens
in the presence of specific IgE resulting in effective T
cell activation at low concentrations of allergen.
“Blocking” IgG antibodies interfere with the interac-
tion and the assay simulates the process in vitro.
Allergen-IgE complexes are incubated with an EBV-
transformed B-cell line and complexes bound to
CD23 on the surface of cells are detected by flow cy-
tometry. Inhibition of allergen-IgE complex binding
to CD23 on B cells by addition of serum from patients
who have received allergen-specific immunotherapy
is then quantitated. They have demonstrated that the
Biomarkers for Allergen Immunotherapy
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Fig. 3 Corelation of symptom score and JCP-specific IgE levels, CD203c expression by JCP extract. Thirty pa-
tients with JCP polinosis were evaluated. Relationships between symptom score54 and CAP-RAST titer to JCP, 
symptom score and JCP alergen-induced CD203chigh% were analyzed. Significant corelation was found in the 
later.
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Fig. 4 Changes in JCP-specific IgE levels (a), JCP-specific IgG4 levels (b), JCP-induced basophil hista-
mine release score in HRT (c), and JCP-induced CD203chigh% in basophils (d) after rush immunotherapy 
in patients with JCP polinosis. ＊P＜0.05, ＊＊P＜0.01, Dunn's multiple comparison test (adapted from 
reference 49 with permission). Two subjects in whom basophils did not respond to stimulation with an 
anti-IgE antibody (non-responders) were excluded from the analysis for HRT and CD203c.
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IgE-FAB assay have high specificity and sensitivity to
diagnose clinical responses to immunotherapy. Re-
cently, several other studies utilize the method to
monitor efficacy of immunotherapy.21,40
ALLERGEN-INDUCED EXPRESSION OF
CD203c ON BASOPHILS
Basophils play important roles in allergic diseases in
effector phase by liberating mediators like histamine
as well as in induction phase by producing Th2 cy-
tokines, IL-4 and IL-13.41 Upon activation through
cross-linking of FcεRI by allergen, basophils rapidly
express surface molecules such as CD63 and CD203c
prior to the mediator and cytokine release. Flowcy-
tometry-based tests for peripheral blood basophils
can easily quantify these in vitro reactions, which pre-
sumably represent their in vivo activity. We utilized a
commercial kit, Allergenicity Kit (Beckman Coulter,
Fullerton, CA, USA), to detect expression of a baso-
phil activation marker, CD203c. CD203c belongs to a
family of ecto-nucleotide pyrophoshatasephosphodi-
esterases (E-NPPs)42,43 and has been described as
being selectively expressed on basophils, mast cells
and their CD34+ progenitors.44,45 Since CRTH2, a
prostaglandinD2 receptor, is selectively expressed on
basophils, Th2 cells, and eosinophils,46,47 the kit iden-
tifies basophils as CD3-negative and CRTH2-positive
fractions from whole blood samples and measures
fluorescent intensity of CD203c that is enhanced by
cross-linking of surface-bound IgE molecules (Fig. 2).
As CD203c is rapidly up-regulated after allergen chal-
lenge in sensitized patients and the levels of up-
regulation are well correlated with their symptoms
(Fig. 2, 3), it has been proposed as a new tool for al-
lergy diagnosis.44,48 An important characteristic of the
kit is that it employs whole blood during incubation
with allergen, which not only detects specific IgE an-
tibodies on basophils but also allows serum and other
factors, possibly “inhibitory” factors induced by im-
munotherapy, in the blood to modify the reaction.
We recently found that induced expression of
CD203c by Japanese cedar pollen (JCP) extract de-
creased after rush immunotherapy (RIT) in patients
with JCP pollinosis without decrease in specific IgE
levels to JCP.49 We also found that significant eleva-
tion in JCP-specific IgG4 titers after RIT. There was
no changes in JCP-induced histamine release from
purified basophils50 after RIT (Fig. 4). In passive sen-
sitization experiments, the patients’ sera obtained
both before and after RIT showed essentially similar
sensitizing capacity for basophils, corroborating the
fact that specific IgE did not change. In contrast, ba-
sophil degranulation in response to the pollen extract
was effectively suppressed by addition of post-RIT se-
rum samples, which correspond with the elevation of
specific IgG4 in the serum.51 These results suggest
that the CD203c test can detect blocking activity of
IgG antibodies and other factors induced by immuno-
therapy. We also extend application of the assay to di-
agnosis of food allergy, especially of tolerance. Al-
though specific IgE levels roughly predict sensitivity
to food allergens,52 markers that represent tolerance
levels during outgrow phase of food allergy in child-
hood are not well-known. We found that the CD203c
test effectively predicts sensitivity as well as tolerance
to egg, milk (manuscript in preparation), and wheat53
in children with food allergy.
CONCLUSIONS
Allergen immunotherapy is a promising disease-
modifying therapy for allergic diseases including
Japanese cedar pollinosis. To successfully initiate,
maintain, and complete immunotherapy, predictive
biomarkers have to be developed. Some prospects of
biomarkers in the mechanisms of immunotherapy
were reviewed in this article. Measurement of “block-
ing” activity of IgG such as IgE-facillitated allergen
binding assay may efficiently monitor treatment effect
of immunotherapy. Quantification of enhanced ex-
pression of CD203c on basophils employing whole
blood during reaction with allergen may represent
not only sensitization status but also tolerance levels
in immunotherapy-treated patients. Larger scale stud-
ies are needed to standardize the CD203c assay for
general laboratory use.
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